Pfizer showed better-than-expected results for 2Q24, and raised its outlook for the full year 2024. After peaking at 4% in pre-market trading, the company is currently gaining just less than 0.5%.
2Q24 was the first quarter since the record second quarter of 2022 (when revenues peaked thanks to sales driven by the COVID-19 pandemic) in which the company managed to achieve positive year-on-year revenue growth. Revenues rose to $13.28 billion (+3% y/y), despite a decline in revenues generated in the COVID-related segment (sales of the Comirnata vaccine fell 87% y/y). Excluding this segment, revenues grew 14% y/y.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appCurrently, Pfizer's results are most strongly influenced by the anticoagulant drug Eliquis, with sales of $1.88 billion. The company also achieved strong growth in its oncology segment and has plans to continue its strong growth.
Strong results for 2Q24 led the company to raise its forecast for the full year 2024, with revenue estimates rising to $59.5-62.5 billion (vs. $58.5 - $61.5 billion previously) and adjusted earnings per share projected by the company at $2.45 - $2.65 (vs. $2.15 - $2.35 previously). Excluding the COVID-19 segment, this implies a sales growth rate of 9-11%.
2Q24 RESULTS
- Revenue $13.28 billion, estimates $13 billion
- Adjusted earnings per share: $0.60, estimates $0.46
- Comirnata revenues $195 million, estimates $216.6 million
- Paxlovid revenues $251 million, estimates $244.7 million
- Ibrance revenues $1.13 billion, estimates $1.14 billion
- Eliquis revenues $1.88 billion, estimates $1.89 billion
- Vyndaqel family revenues $1.32 billion, estimates $1.11 billion
- Enbrel revenues $179 million, estimates $181 million
- Xeljanz revenues $303 million, estimates $406.9 million
- Inlyta revenues $252 million, estimates $256.2 million
- Adjusted R&D: costs $2.67 billion, estimates $2.83 billion
- Adjusted SI&A: $3.67 billion, estimates $3.48 billion
2024 OUTLOOK:
- Revenues: $59.5-62.5 billion (previous: $58.5-61.5 billion); estimates: $61 billion
- Adjusted R&D costs: $11-$12 billion
- Adjusted SI&A: $13.8-$14.8 billion
- Adjusted earnings per share: $2.45-$2.65 (previously $2.15-$2.35)
Pfizer continues gains today, approaching the resistance level near $31.41. Source: xStation 
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
